<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096694</url>
  </required_header>
  <id_info>
    <org_study_id>A5205</org_study_id>
    <secondary_id>10187</secondary_id>
    <secondary_id>ACTG A5205</secondary_id>
    <nct_id>NCT00096694</nct_id>
  </id_info>
  <brief_title>Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women</brief_title>
  <official_title>A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Oral contraceptives (OCs) are not a good option for some HIV infected women because of the&#xD;
      potential for drug interactions between OCs and anti-HIV drugs; additionally, OCs may&#xD;
      increase the risk of transmitting HIV to sexual partners. Levonorgestrel is commonly&#xD;
      prescribed as part of a combination OC. An intrauterine device (IUD) is a device inserted in&#xD;
      a woman's uterus to prevent pregnancy. The purpose of this study is to determine the effect&#xD;
      of a levonorgestrel-releasing IUD on the amount of HIV present in an HIV infected woman's&#xD;
      cervix after 4 weeks of IUD use.&#xD;
&#xD;
      Study hypothesis: There will be no increase in genital tract HIV RNA and DNA after placement&#xD;
      of the levonorgestrel IUD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected women face the challenges of preventing both pregnancy and HIV transmission to&#xD;
      their sexual partners. However, OCs may interact with antiretroviral therapy (ART), and data&#xD;
      suggest that higher doses of OCs may increase cervical shedding of HIV-1, which may increase&#xD;
      an HIV infected woman's infectiousness to her sexual partners. A physical barrier&#xD;
      contraceptive would be useful to HIV infected women to circumvent the problems associated&#xD;
      with concurrent use of OCs and ART. The levonorgestrel IUD has proved highly effective in&#xD;
      preventing unwanted pregnancies in HIV uninfected women since its introduction in the United&#xD;
      States in 1999. This study will evaluate the effect of the levonorgestrel IUD on HIV viral&#xD;
      load in an HIV infected woman's cervix after 4 weeks of IUD use.&#xD;
&#xD;
      This study will last approximately 48 weeks; there will be 4 study visits. At screening,&#xD;
      participants will undergo medical and medication history assessment; a complete physical&#xD;
      exam; a pelvic exam, including genital tract sample collection; blood collection; sexually&#xD;
      transmitted disease (STD) testing; and a Pap smear, if needed. The levonorgestrel IUD will be&#xD;
      inserted into the participant's uterus at study entry. At study entry and at Weeks 4, 16, and&#xD;
      48, participants will undergo a targeted physical exam; a pelvic exam, including genital&#xD;
      tract sample collection; and blood collection. Participants will be given a menstrual diary&#xD;
      at the start of the study and at each study visit and will be asked to document all menstrual&#xD;
      cycles they have for the duration of the study.&#xD;
&#xD;
      To be eligible for this study, participants may not have had ART within 90 days prior to&#xD;
      study entry. However, after the Week 4 study visit, participants may reinitiate (if they were&#xD;
      on ART more than 90 days prior to study entry) or initiate (if they are ART naive) ART, if&#xD;
      deemed necessary to do so by their physicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign and magnitude of difference in endocervical HIV viral load from baseline to Week 4 post-IUD insertion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of discontinuation of IUD use in the year following insertion</measure>
  </primary_outcome>
  <enrollment>41</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-releasing intrauterine device (IUD)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Willing and able to delay initiation or reinitiation of antiretroviral therapy until&#xD;
             after Week 4 study visit&#xD;
&#xD;
          -  Unlikely to develop a clinical indication to start antiretroviral therapy within 4&#xD;
             weeks of study entry&#xD;
&#xD;
          -  CD4 count of 200 cells/mm3 or more&#xD;
&#xD;
          -  Viral load of 10,000 copies/ml or more within 90 days prior to study entry&#xD;
&#xD;
          -  Endocervical viral load of 2,500 copies/ml or more within 90 days prior to study entry&#xD;
&#xD;
          -  History of prior pregnancy lasting at least 20 weeks&#xD;
&#xD;
          -  Willing to continue any current use of hormonal contraceptives, except&#xD;
             medroxyprogesterone acetate, until after Week 4 study visit&#xD;
&#xD;
          -  Start of last menstrual period within 7 days prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antiretroviral medications within 90 days prior to study entry&#xD;
&#xD;
          -  AIDS diagnosis, including CD4 count of less than 200 cells/mm3&#xD;
&#xD;
          -  Cervicitis, bacterial vaginosis, trichomoniasis, or symptomatic vaginal candidiasis&#xD;
             within 90 days prior to study entry. Participants with any of these infections within&#xD;
             90 days prior to study entry are not excluded if they have received appropriate&#xD;
             treatment and have documented resolution of the infection.&#xD;
&#xD;
          -  Acute or history of pelvic inflammatory disease, chlamydia, or gonorrhea in the year&#xD;
             prior to study entry&#xD;
&#xD;
          -  Abnormal Pap smear requiring treatment in the year prior to study entry&#xD;
&#xD;
          -  History of ectopic pregnancy or a condition that would predispose the participant to&#xD;
             ectopic pregnancy&#xD;
&#xD;
          -  Known uterine anomaly, including fibroids&#xD;
&#xD;
          -  Known or suspected breast cancer&#xD;
&#xD;
          -  Acute liver disease or liver tumor&#xD;
&#xD;
          -  Have previously inserted IUD that has not been removed&#xD;
&#xD;
          -  Fungal infection in the genitals&#xD;
&#xD;
          -  Genital bleeding of unknown cause&#xD;
&#xD;
          -  Endometritis or infected abortion within 90 days of study entry&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the IUD used in this study&#xD;
&#xD;
          -  Current drug or alcohol abuse that, in the opinion of the investigator, may interfere&#xD;
             with the study&#xD;
&#xD;
          -  Serious infection or other serious medical illness that is potentially life&#xD;
             threatening and requires systemic therapy or hospitalization within 14 days of study&#xD;
             entry&#xD;
&#xD;
          -  Use of etonogestrel and ethinyl estradiol vaginal ring (NuvaRing) within 30 days prior&#xD;
             to study entry&#xD;
&#xD;
          -  Medroxyprogesterone acetate within 90 days prior to study entry&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Milu Kojic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Immunology/Infectious Disease, The Miriam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>77555-0435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSTAR, Family Healthcare Ctr.</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr., ACTU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hosp.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVandPregnancy_FS_en.pdf</url>
    <description>Click here for more information on HIV and pregnancy</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/ElVIHYElEmbarazo_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca del VIH y el embarazo</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/UnderstandingHIVPrevention_FS_en.pdf</url>
    <description>Click here for more information on understanding HIV prevention</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/LaPrevencionDelVIH_FS_sp.pdf</url>
    <description>Haga clic aquí para más información acerca de la prevención del VIH</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1534</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español</description>
  </link>
  <reference>
    <citation>Bird ST, Harvey SM, Maher JE, Beckman LJ. Acceptability of an existing, female-controlled contraceptive method that could potentially protect against HIV: a comparison of diaphragm users and other method users. Womens Health Issues. 2004 May-Jun;14(3):85-93.</citation>
    <PMID>15193636</PMID>
  </reference>
  <reference>
    <citation>Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK, Overbaugh J, Panteleeff DD, Weiner DH, Kreiss JK. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS. 1999 Oct 22;13(15):2091-7.</citation>
    <PMID>10546862</PMID>
  </reference>
  <reference>
    <citation>Stuart GS, Castaño PM. Sexually transmitted infections and contraceptives: selective issues. Obstet Gynecol Clin North Am. 2003 Dec;30(4):795-808. Review.</citation>
    <PMID>14719851</PMID>
  </reference>
  <reference>
    <citation>Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, Chohan B, Lavreys L, Ndinya-Achola J, Kreiss JK. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004 Jan 23;18(2):205-9.</citation>
    <PMID>15075537</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 12, 2004</study_first_submitted>
  <study_first_submitted_qc>November 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2004</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrauterine Device</keyword>
  <keyword>IUD</keyword>
  <keyword>Contraceptive</keyword>
  <keyword>Levonorgestrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

